Skip to main content

ChemoMetec A/S (CHEMM.CO)

Euronext Healthcare Medical - DevicesView data quality →
54.0Fair

ValueMarkers Composite Index

Top 47%#23,548 of 44,714
Overvalued

41% above intrinsic value ($34)

UndervaluedFair ValueOvervalued
Piotroski
3/9
Weak
Beneish
-
Altman
-
DCF Value
$34
Overvalued
ROIC
27.2%
Strong
P/E
29.8
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

ChemoMetec A/S (CHEMM.CO) — VMCI valuation read

ChemoMetec A/S sits at VMCI 54/100, with the Healthcare sector median at 50. That 4-point spread is the first thing to note on CHEMM.CO: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on CHEMM.CO are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on CHEMM.CO: CHEMM.CO trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 12.0% sits 2.0pp above the Healthcare median (10.0%). The Risk read: net debt to EBITDA of -1.5x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

CHEMM.CO rose 1.7% over the trailing 7 days, with a -0.7% read on a 30-day basis.

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Allerød, Denmark.

CEO: Martin Helbo Behrens184 employeesDKchemometec.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in CHEMM.CO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.